Select Language
COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global intravenous solutions market reached a value of US$ 13.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 18.6 Billion by 2027, exhibiting a CAGR of 5.96% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Intravenous (IV) solutions are supplemental fluids comprising water, electrolytes, sugar, and medications. They are given to patients according to their requirements, medical condition, age, and body size to restore fluid volume and treat electrolyte balance. At present, they are widely used in IV therapy to replace electrolyte losses, administer drugs and blood products, and supply essential nutrients to the intravascular fluid compartment.
Due to the sudden outbreak of coronavirus disease (COVID-19), there is a rise in the demand for IV solutions worldwide to provide essential nutrients to patients in the intensive care unit (ICU). Apart from this, the increasing number of people who have diabetes, cancer, gastrointestinal disorder, and neurological diseases represents another major growth-inducing factor. Moreover, the faster response time and higher efficacy associated with IV solution therapy is contributing to market growth. It is used to overcome chronic dehydration that can cause fatigue, memory problems, irritability, and other medical conditions. This, along with the increasing participation of individuals in physical activities, is influencing the adoption of IV solutions for a fast recovery. IV solutions are also utilized to improve skin conditions and treat migraines and hangovers. Besides this, leading manufacturers are introducing easy-to-use, portable product variants that can be used as drips at home. Additionally, due to rising environmental concerns, they are developing premixed solutions that reduce the amount of packaging waste. Furthermore, rising investments by health agencies of numerous countries in the healthcare sector are anticipated to create a favorable market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global intravenous solutions market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on type and nutrients.
Breakup by Type:
Total parenteral nutrition is currently the most preferred type of IV solution as it helps prevent malnutrition and maintain energy.
Breakup by Nutrients:
Breakup by Region:
Presently, North America enjoys the leading position in the market due to the increasing prevalence of chronic diseases in the region.
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Ajinomoto Co., Inc., B. Braun Melsungen AG, Baxter International, Inc., Grifols S.A., and Otsuka Pharmaceutical.
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2021 |
| Historical Period | 2016-2021 |
| Forecast Period | 2022-2027 |
| Units | US$ Billion |
| Segment Coverage | Type, Nutrients, Region |
| Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Companies Covered | Ajinomoto Co., Inc., B. Braun Melsungen AG, Baxter International, Inc., Grifols S.A., and Otsuka Pharmaceutical |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
We expect the global intravenous solutions market to grow at a CAGR of 5.96% during 2022-2027.
The growing awareness towards the faster response time and higher efficacy of IV solution therapy represents one of the factors catalyzing the global intravenous solutions market.
Sudden outbreak of the COVID-19 pandemic has led to the increasing demand for intravenous solutions for health recovery of patients affected by the coronavirus to provide salt, sugar, and water directly into their venous circulation.
Based on the type, the global intravenous solutions market has been segmented into partial parenteral nutrition and total parenteral nutrition. Currently, total parental nutrition holds the majority of the total market share.
Based on the nutrients, the global intravenous solutions market can be divided into carbohydrates, salts and electrolytes, minerals, vitamins, and amino acids. Among these, salts and electrolytes exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global intravenous solutions market include Ajinomoto, B. Braun Melsungen, Baxter International Inc., Grifols, and Otsuka Pharmaceutical.
10% Free customization
Purchase Options
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at
sales@imarcgroup.com